

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

You're editing your response. Sharing this URL allows others to also edit your response. **FILL OUT A NEW RESPONSE**
YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use

proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <http://www.jmir.org/2011/4/e126/>

doi: 10.2196/jmir.1923

PMID: 22209829

* Required

Your name *

First Last

Emily Hébert

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

University of Oklahoma Health Science

Your e-mail address *

abc@gmail.com

emily-hebert@ouhsc.edu

Title of your manuscript *

Provide the (draft) title of your manuscript.

A pilot randomized controlled trial of a just-in-time adaptive intervention
for smoking cessation

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Smart-T2

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

v1

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.



**FILL OUT A NEW
RESPONSE**

Accessibility *

Can an enduser access the intervention presently?

- ☐ access is free and open
- ☒ access only for special usergroups, not open
- ☐ access is open to everyone, but requires payment/subscription/in-app purchases
- ☐ app/intervention no longer accessible
- ☐ Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

smoking

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

smoking cessation

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

feasibility, acceptability of app



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?

- ☒ Approximately Daily
- ☐ Approximately Weekly
- ☐ Approximately Monthly
- ☐ Approximately Yearly
- ☐ "as needed"
- ☐ Other:



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**

Approx. Percentage of Users (starters) still using the app as recomn

☐ unknown / not evaluated

☐ 0-10%

☐ 11-20%

☐ 21-30%

☐ 31-40%

☐ 41-50%

☐ 51-60%

☐ 61-70%

☒ 71%-80%

☐ 81-90%

☐ 91-100%

☐ Other:



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**

Overall, was the app/intervention effective? *

- ☐ yes: all primary outcomes were significantly better in intervention group vs control
- ☐ partly: SOME primary outcomes were significantly better in intervention group vs control
- ☒ no statistically significant difference between control and intervention
- ☐ potentially harmful: control was significantly better than intervention in one or more outcomes
- ☐ inconclusive: more research is needed
- ☐ Other:

Article Preparation Status/Stage *

At which stage in your article preparation are you currently (at the time you fill in this form)

- ☐ not submitted yet - in early draft status
- ☒ not submitted yet - in late draft status, just before submission
- ☐ submitted to a journal but not reviewed yet
- ☐ submitted to a journal and after receiving initial reviewer comments
- ☐ submitted to a journal and accepted, but not published yet
- ☐ published
- ☐ Other:

You're editing your response. Sharing this URL allows others to also edit your response.



**FILL OUT A NEW
RESPONSE**

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- ☐ not submitted yet / unclear where I will submit this
- ☒ Journal of Medical Internet Research (JMIR)
- ☐ JMIR mHealth and UHealth
- ☐ JMIR Serious Games
- ☐ JMIR Mental Health
- ☐ JMIR Public Health
- ☐ JMIR Formative Research
- ☐ Other JMIR sister journal
- ☐ Other:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- ☒ Pilot/feasibility
- ☐ Fully powered



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

☐ no ms number (yet) / not (yet) submitted to / published in JMIR

☒ Other: 16907

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

☒ yes

☐ Other:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

subitem not at all important

You're editing your response. Sharing this URL allows others to also edit your response.

☐ ☐ ☐ ☐ ☒ essential

FILL OUT A NEW RESPONSE



Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"mobile"

1a-ii) Non-web-based components or important co-interventions in

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

subitem not at all
important



essential

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All non-web components (e.g., NRT) were given to all 3 groups and are not unique to the intervention.

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"for smoking cessation"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all
important



essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants in the Smart-T2 group received tailored treatment messages at the completion of each EMA. Both Smart-T2 and QuitGuide apps offered on-demand smoking cessation treatment."

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

1b-ii) Level of human involvement in the METHODS section of the A

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all
important



essential

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All study participants received nicotine patches and gum, and all participants were asked to complete EMAs 5 times a day on study provided smartphones for 5 weeks. Participants in the Smart-T2 group received tailored treatment messages at the completion of each EMA. Both Smart-T2 and QuitGuide apps offered on-demand smoking

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-fa

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Adults smokers who attended a clinic-based tobacco cessation program "

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all
important



essential

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A total of 14 (17.3%) participants were biochemically confirmed 7-day point prevalence abstinent at 12 weeks post-quit (Smart-T2: 22.2%, QuitGuide: 14.8%, Usual Care: 14.8%), with no significant differences across groups. Participants in the Smart-T2 group rated the app positively, with most participants agreeing that they can rely on the app to help them quit smoking and endorsed the belief that the app would help them stay quit, and these responses were not significantly different from the ratings given by participants in the usual care group."

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all
important



essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dynamic smartphone apps that tailor intervention content in real-time may increase user engagement and exposure to treatment related materials. The results of this pilot RCT suggest that smartphone-based smoking cessation treatments may be capable of providing similar outcomes to traditional, in-person counseling.

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all
important



essential

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Although a majority of cigarette smokers are interested in quitting, very few use evidence-based cessation treatments...Mobile technology has enormous potential to overcome many of the barriers that have hampered use of other empirically supported smoking cessation treatments among lower SES individuals."

2a-ii) Scientific background, rationale: What is known about the (typ

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"JITAs aim to address moments of vulnerability for unhealthy behaviors (such as high-risk situations) by providing support in real-time through mobile technology...While these JITAs show great potential for providing widely accessible, innovative treatment for smoking cessation, most JITAs remain untested.."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The purpose of the current study was to compare, in a pilot randomized controlled trial, the feasibility and preliminary effectiveness of a smartphone-delivered JITA for smoking cessation (Smart-T2) to the NCI QuitGuide app and usual care in-person tobacco cessation treatment."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"At baseline, participants were randomized into one of the following treatment groups: 1) Smart-Treatment (Smart-T2) phone-based automated smoking cessation treatment, 2) National Cancer Institute (NCI) QuitGuide app, or 3) usual tobacco cessation clinic care (TTRP)."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A - no changes made after trial commencement

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A - no relevant bug fixes, downtime, or content changes

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Individuals were eligible to participate if they: 1) demonstrated > 6th grade English literacy level, 2) were willing to quit smoking 7 days from their first visit, 3) were ≥ 18 years of age, 4) had an expired carbon monoxide (CO) level > 7 ppm suggestive of current smoking, 5) reported smoking ≥ 5 cigarettes per day, 6) were willing and able to attend 4 in-person assessment sessions, and 7) had no contraindications for over the counter NRT (i.e., uncontrolled blood pressure, myocardial infarction within the past two weeks, or current pregnancy or plans to become

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Computer literacy was not evaluated but participants were provided with study phones and were trained to use the app, "All participants were provided with a smartphone (Samsung Galaxy On5) at the baseline visit, were trained to use their assigned app by study staff..."

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all
important



essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were followed for 13 weeks (1 week pre-quit through 12 weeks post-quit), and completed in-person assessments at the baseline, quit-date (1 week after baseline), and 4 and 12 weeks post-quit visits..." "Participants were prompted to complete EMAs 5 times per day (4 random assessments + 1 daily diary) for five weeks (1 week pre-quit and 4

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

subitem not at all
important



essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were provided with a smartphone preloaded with their assigned smoking cessation app and/or the EMA app for 5 weeks.." "were trained to use their assigned app by study staff, and were asked to carry the phone with them at all times."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Individuals were screened for eligibility following provider or self-referral to the Tobacco Treatment Research Program (TTRP)..."

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

subitem not at all
important



essential

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"completed in-person assessments at the baseline, quit-date (1 week after baseline), and 4 and 12 weeks post-quit visits..." "At each in-person visit following the scheduled quit date, participants were asked if they smoked "even a puff" during the past 7 days. Abstinence was verified via expired carbon monoxide (CO) at each visit using a Vitalograph CO

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

subitem not at all
important



essential

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants came from a subsample of individuals who were already

referred to a tobacco research clinic affiliated with a university.

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

subitem not at all
important

☐☐☒☐☐

essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Programming and technological support was provided through the mHealth Shared Resource of the Stephenson Cancer Center via an NCI Cancer Center Support Grant "

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

subitem not at all
important

☐☐☒☐☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Addressed in introduction and then in methods "The Smart-T2 app has been described in detail elsewhere..." with citation.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

subitem not at all
important



essential

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Intervention described as 2nd version

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Outcome data collected in person and biochemically verified

5-v) Ensure replicability by publishing the source code, and/or provi

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

subitem not at all
important

☐☐☒☐☐

essential

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Screenshot included in text, algorithm described in prior paper and referenced in introduction.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, [webcitation.org](https://www.webcitation.org), and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all
important

☒☐☐☐☐

essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was a pilot study and the intervention is not yet available to the public. A screenshot of the intervention is included in the paper.

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all
important



essential

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were provided with a smartphone preloaded with their assigned smoking cessation app and/or the EMA app"

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

5-viii) Mode of delivery, features/functionalities/components of the

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

subitem not at all
important



essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Smart-T2 is a multi-component adjunctive smoking cessation app featuring: 1) an algorithm that evaluates current risk of smoking lapse based on EMA responses and pushes tailored messages to help participants cope, 2) a "Quit Tips" button offering cessation advice, coping strategies, and quitting benefits, 3) a "Medications" button offering information about smoking cessation medications, 4) a "Phone a Counselor" button that calls the free Oklahoma Tobacco Help Line, 5) daily treatment messages (e.g., your quit date is tomorrow), 6) a button to request additional NRT through the EMA app home screen."

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

subitem not at all
important



essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Intervention messages were delivered at the completion of every EMA. "

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all
important



essential

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"a "Call Staff" function/button that automatically called study staff
when/if participants had problems with the phone"

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all
important



essential

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were prompted to complete EMAs 5 times per day (4 random assessments + 1 daily diary) for five weeks..." "when EMA responses indicated a high risk of imminent lapse, participants received a message to chew a piece of nicotine gum to reduce their risk for lapse"

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"all participants received a 2 week supply of over the counter NRT (i.e., patches and gum) for the initial post-quit period. Upon request, participants were offered up to 8 additional weeks of nicotine patches and up to 10 additional weeks of nicotine gum."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"At each in-person visit following the scheduled quit date, participants were asked if they smoked "even a puff" during the past 7 days. Abstinence was verified via expired carbon monoxide (CO) at each visit using a Vitalograph CO monitor. Self-reported abstinence over the specified time period and a CO reading below 8 ppm (10 ppm on the quit date) were required to be considered abstinent"... "At the quit date and 4-week post-quit visits, participants also answered questions to evaluate their satisfaction and therapeutic alliance with their smoking cessation counselor or assigned smoking cessation smartphone application."

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW RESPONSE

6a-i) Online questionnaires: describe if they were validated for online use

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

subitem not at all
important



essential

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Questionnaires were taken in person (not via web) or were closed system within mobile phone. Majority of CHERRIES items do not apply, but others (such as description of incentives) are presented in methods section.

6a-ii) Describe whether and how "use" (including intensity of use/dosage)

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



**FILL OUT A NEW
RESPONSE**

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

"Among the 27 participants in the Smart-T2 group, 14 participants (51.9%) accessed the on-demand medication tips, and 20 participants (74.1%) accessed the on-demand quit tips. Once a participant selected a specific category of message, they could click "next" to view multiple messages within that category. The most frequently selected tip types were "Coping with Others Smoking" and "Harms of Smoking" (selected an average of 2.0 times during the intervention period), followed by the "Coping with Mood" (selected an average of 1.8 times), and the "Medication: Nicotine Gum" (selected an average of 1.5 times)..." "Among the participants in the QuitGuide treatment group, 21 of the 27 participants (77.8%) opened the app an average of 9.9 times (SD=7.4) and interacted with the application for an average of 10.6 days (SD=4.8; range= 2-20 days) during the EMA

6a-iii) Describe whether, how, and when qualitative feedback from p

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

subitem not at all
important



essential

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Qualitative feedback not obtained.

6b) Any changes to trial outcomes after the trial commenced, with reasons



You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - trial outcomes did not change.

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account

Describe whether and how expected attrition was taken into account when calculating the sample size.

subitem not at all
important



essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was a pilot study that was not powered to detect any differences between groups.

7b) When applicable, explanation of any interim analyses and stopping guidelines

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - no interim analyses conducted.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"At baseline, participants were randomized into one of the following treatment groups: 1) Smart-Treatment (Smart-T2) phone-based automated smoking cessation treatment, 2) National Cancer Institute (NCI) QuitGuide app, or 3) usual tobacco cessation clinic care (TTRP)

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - simple randomization used for pilot.

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"using a simple computer-generated randomization scheme"

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"using a simple computer-generated randomization scheme"

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

You're editing your response. Sharing this URL allows others to also edit your response.



**FILL OUT A NEW
RESPONSE**

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

subitem not at all
important



essential

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No blinding done.

11a-ii) Discuss e.g., whether participants knew which intervention was

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

subitem not at all
important



essential

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were informed that the study purpose was to compare 3 smoking cessation treatment approaches and were provided with a detail outline of study procedures, and written informed consent was obtained. "

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All participants were provided with a smartphone preloaded with their assigned smoking cessation app and/or the EMA app for 5 weeks. In addition, all participants received a 2 week supply of over the counter NRT (i.e., patches and gum) for the initial post-quit period. Upon request, participants were offered up to 8 additional weeks of nicotine patches and up to 10 additional weeks of nicotine gum."

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Descriptive statistics were used to summarize participant demographics and engagement with the smartphone app. Comparisons between groups were made with Chi-square tests or ANOVA with Fisher's Least Significant Difference post-hoc test, as appropriate. All analyses were conducted in

IBM SPSS version 26."

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE



12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all
important



essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Imputation not used. "Participants who did not provide biochemical confirmation of abstinence (e.g., they did not attend the visit) were considered smoking."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



X26-i) Comment on ethics committee approval

subitem not at all
important



essential

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study procedure was approved by the Institutional Review Board at the University of Oklahoma Health Sciences Center."

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

subitem not at all
important



essential

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were informed that the study purpose was to compare 3 smoking cessation treatment approaches and were provided with a detail outline of study procedures, and written informed consent was obtained.

You're editing your response. Sharing this URL allows others to also edit your response.



**FILL OUT A NEW
RESPONSE**

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

subitem not at all
important



essential

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All data collected through the smartphone app were de-identified and encrypted. "

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Ninety-eight individuals were assessed for eligibility. Of those, 84 were eligible and consented to participate in the study. Three individuals dropped out of the study before the baseline visit was completed, thus all analyses include the remaining 81 participants"

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



13b) For each group, losses and exclusions after randomisation, together with reasons



Does your paper address CONSORT subitem 13b? (NOTE: Preferably

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

CONSORT diagram included as Figure 2.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

subitem not at all
important



essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

CONSORT diagram included as Figure 2.

14a) Dates defining the periods of recruitment and follow-up



You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Data collection took place between May 2017 and October 2018. Participants were followed for 13 weeks (1 week pre-quit through 12 weeks post-quit), and completed in-person assessments at the baseline, quit-date (1 week after baseline), and 4 and 12 weeks post-quit visits. "

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

subitem not at all
important



essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. You're editing a response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**



15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1 includes demographic characteristics.

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

subitem not at all
important



essential

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Demographics included in table 1, smartphones were provided so other potential access issues were not applicable.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE

16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N’s (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

subitem not at all
important



essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N’s reported in all tables.

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at all
important



essential

You’re editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Pilot study so primary outcomes were related to feasibility and app perceptions, but smoking outcomes were intent to treat. "A total of 37 (45.7%) participants were confirmed abstinent (7-day point prevalence, intent to treat) at 4 weeks post-quit (Smart-T2: 22.2%, QuitGuide: 25.9%, Usual Care: 25.9%), and 14 (17.3%) participants were confirmed abstinent at 12 weeks post-quit (Smart-T2: 22.2%, QuitGuide: 14.8%, Usual Care:

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Study not powered to estimate meaningful effect sizes.

17a-i) Presentation of process outcomes such as metrics of use an

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Multiple examples throughout results - "Among the 27 participants in the Smart-T2 group, 14 participants (51.9%) accessed the on-demand medication tips, and 20 participants (74.1%) accessed the on-demand quit tips. Once a participant selected a specific category of message, they could click "next" to view multiple messages within that category. The most frequently selected tip types were "Coping with Others Smoking" and "Harms of Smoking" (selected an average of 2.0 times during the intervention period), followed by the "Coping with Mood" (selected an average of 1.8 times), and the "Medication: Nicotine Gum" (selected an

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - study not powered.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable, only descriptive analyses, none adjusted.

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

subitem not at all
important



essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable, all participants smokers and users of app.

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - intervention not invasive or high risk, no unintended harms occurred.

You're editing your response. Sharing this URL allows others to edit your response.

PULL OUT A NEW
RESPONSE



19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

subitem not at all
important



essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - no privacy breaches occurred.

19-ii) Include qualitative feedback from participants or observations

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at all
important



essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable - will be considered in future study.

DISCUSSION
You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**



22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all
important



essential

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study demonstrates the feasibility and acceptability of Smart-T2, a smartphone-based, just-in-time adaptive intervention for smoking cessation. Participants across all three treatment groups (i.e., Smart-T2, QuitGuide, and usual care) were largely compliant with the EMA protocol, and a majority of participants in the Smart-T2 group engaged with on-demand treatment content and utilized the app to order additional nicotine replacement therapy. Although the study was not powered to detect significant differences in smoking cessation outcomes or nicotine replacement therapy use across the three treatment groups, the results of this pilot RCT suggest that smartphone-based smoking cessation treatments may be capable of providing similar outcomes to traditional,

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

subitem not at all
important



essential

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"First, the Smart-T2 app did not save the duration of counseling calls that were initiated through the app. Thus, we are unable to determine if use of the "Call Counselor" button was representative of legitimate calls to the Oklahoma Tobacco Cessation Helpline. Second, the current pilot trial had a small sample size, which precludes the ability to make definitive conclusions about the effectiveness of the interventions. A future study will compare the effectiveness of the Smart-T2 and QuitGuide intervention

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"First, the Smart-T2 app did not save the duration of counseling calls that were initiated through the app. Thus, we are unable to determine if use of the "Call Counselor" button was representative of legitimate calls to the Oklahoma Tobacco Cessation Helpline. Second, the current pilot trial had a small sample size, which precludes the ability to make definitive conclusions about the effectiveness of the interventions."

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all
important



essential

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"However, the studies differed in terms of method of measuring abstinence (i.e., self-report versus biochemical verification), and in terms of treatment protocol (i.e., QuitGuide participants in the current study were provided with nicotine replacement therapy); thus it is unclear if these results will generalize to a larger, fully-powered sample." ... "Second, the current pilot trial had a small sample size, which precludes the ability to make definitive conclusions about the effectiveness of the interventions."

21-ii) Discuss if there were elements in the RCT that would be different

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

subitem not at all
important



essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Pilot trial, just testing feasibility, not enough data to know how it would be different in a routine application setting.

OTHER INFORMATION

You're editing your response. Sharing this URL allows others to also edit your response.

23) Registration number and name of trial registry

FILL OUT A NEW
RESPONSE

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ClinicalTrials.gov identifier: NCT02930200"

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Programming and technological support was provided through the mHealth Shared Resource of the Stephenson Cancer Center via an NCI Cancer Center Support Grant (P30CA225520). Data analysis and manuscript preparation were additionally supported through K99DA046564 (to ETH), and through the Oklahoma Tobacco Settlement Endowment Trust (TSET) grant 092-016-0002. The contents of the manuscript are solely the responsibility of the authors and do not

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE



X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

subitem not at all
important

☐☐☒☐☐

essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Conflicts of Interest - None declared."

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your ma

☐ yes, major changes

☒ yes, minor changes

☐ no

What were the most important changes you made as a result of usir

Adding information about participant training in the app

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW
RESPONSE



How much time did you spend on going through the checklist INCL

1-2 hours

As a result of using this checklist, do you think your manuscript has

☒ yes

☐ no

☐ Other:

Would you like to become involved in the CONSORT EHEALTH group

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

☐ yes

☒ no

☐ Other:

Any other comments or questions on CONSORT EHEALTH

Your answer



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**

STOP - Save this form as PDF before you click submit



To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !



Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. [Report Abuse](#) - [Terms of Service](#) - [Privacy Policy](#)

Google Forms

You're editing your response. Sharing this URL allows others to also edit your response.



FILL OUT A NEW
RESPONSE



You're editing your response. Sharing this URL allows others to also edit your response.

**FILL OUT A NEW
RESPONSE**